CBIO SCHEDULE 13G/A: SEC filing
Balyasny Asset Management L.P. and affiliated reporting persons
Filed with the SEC on · accession 0001172661-26-005039
CBIO filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Balyasny Asset Management L.P. and affiliated reporting persons filed an amended Schedule 13G indicating beneficial ownership of approximately 4.34% (1,611,958 shares) of Crescent Biopharma, Inc. common stock as of September 30, 2026. The stock moved -4.6% by the first close after the filing.
Summary of the filing
Balyasny Asset Management L.P. and affiliated reporting persons filed an amended Schedule 13G indicating beneficial ownership of approximately 4.34% (1,611,958 shares) of Crescent Biopharma, Inc. common stock as of September 30, 2026. The filing is a passive investment disclosure with no intent to influence control of the issuer.
Key details
How CBIO stock reacted
Close before
$14.15
Nov 13, 2026
First close after
-4.59%
$13.50
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for CBIO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CBIO?
Click hereFrequently asked questions
What did CBIO file with the SEC on Nov 16, 2026?
CBIO filed a SCHEDULE 13G/A (SEC filing). Balyasny Asset Management L.P. and affiliated reporting persons filed an amended Schedule 13G indicating beneficial ownership of approximately 4.34% (1,611,958 shares) of Crescent Biopharma, Inc. common stock as of September 30, 2026. The filing is a passive investment disclosure with no intent to influence control of the issuer.
How do I read a SCHEDULE 13G/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).
How did CBIO stock react to this filing?
CBIO closed at $14.15 before the filing and $13.50 on Nov 16, 2026 (-4.59%).
Other CBIO SEC filings
Get alerts when CBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days